Heartflow Inc Dossier
|
SectorHealth Care IndustryHealth Information Services Beta (adjusted)1.00 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $48.91Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $4.3B Enterprise Value $4.2B Shares Outstanding 87.4M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary HeartFlow, Inc. (NASDAQ: HTFL) is a pioneer and category leader in AI-driven, non-invasive cardiac diagnostics. Following its successful IPO in August 2025, the company has demonstrated exceptional commercial momentum, highlighted by a 41% YoY revenue surge to $52.6 million in Q1 2026. This growth is underpinned by strong secular tailwinds, including the integration of CCTA into major clinical guidelines and highly favorable Medicare reimbursement policies (such as the doubling of CCTA reimbursement rates and the transition of Plaque Analysis to a Category I CPT code in 2026). While the company remains unprofitable due to heavy investments in scaling its sales footprint and R&D, its high operating leverage and expanding non-GAAP gross margins (reaching 80.5% in Q1 2026) support a clear path toward profitability. The ongoing patent litigation against direct rival Cleerly highlights HeartFlow's defensive moat and commitment to protecting its extensive intellectual property portfolio. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$39.00 Mean target$43.50 High · most bullish analyst$45.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $39.00 Commercial adoption of Plaque Analysis slows down due to intense competition from established medical imaging conglomerates and venture-backed startups. Pricing concessions in the FFR-CT business compress average selling prices more than offset by volume gains. High sales, marketing, and R&D expenses remain elevated, prolonging net losses and accelerating cash burn. Legal expenses escalate significantly due to protracted patent litigation with Cleerly, or an unfavorable court ruling weakens HeartFlow's intellectual property moat. Base CaseCentral scenario $43.50 Matches the consensus meanHeartFlow delivers on its raised FY 2026 revenue guidance of $228M-$232M (representing 29%-32% YoY growth) and achieves a non-GAAP gross margin of approximately 81%. The core FFR-CT business remains highly durable, supported by the established clinical guidelines and favorable reimbursement structures. Plaque Analysis continues its steady adoption curve, contributing $19M-$21M in revenue. Operating expenses as a percentage of revenue continue to decline gradually, keeping the company on track for its midterm profitability targets. Bull CaseUpside scenario $45.00 Rapid clinical adoption of the newly launched Plaque Analysis and PCI Navigator platforms drives revenue significantly above raised FY 2026 guidance. Payer coverage for Plaque Analysis expands rapidly beyond the current ~75% of U.S. covered lives, leading to accelerated monetization of captured CCTA scans. Operational automation and AI-driven efficiencies in the production team push non-GAAP gross margins past the midterm target of 85% ahead of schedule, accelerating the timeline to GAAP profitability. A favorable resolution in the Cleerly patent lawsuit solidifies HeartFlow's market dominance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |